Article Details

With a superstar cardiologist as its CEO, new CRISPR company targets heart disease

Retrieved on: 2019-05-06 17:56:15

Tags for this article:

Click the tags to see associated articles and topics

With a superstar cardiologist as its CEO, new CRISPR company targets heart disease. View article details on hiswai:

Excerpt

<div>Verve Therapeutics, with $58.5 million in seed funding led by GV (formerly <b>Google Ventures</b>), aims to develop CRISPR gene editing therapies as ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up